Have a feature idea you'd love to see implemented?
Let us know!
CMMB Chemomab Therapeutics Ltd
Price (delayed)
$1.65
Market cap
$31.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$24.78M
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of
Highlights
CMMB's EPS has surged by 63% year-on-year and by 13% since the previous quarter
CMMB's net income has surged by 50% year-on-year and by 4% since the previous quarter
CMMB's equity has soared by 63% from the previous quarter but it is down by 10% YoY
Key stats
What are the main financial stats of CMMB
Market
Valuations
Earnings
Shares outstanding
18.86M
Market cap
$31.11M
Enterprise value
$24.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$14.4M
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
-$0.96
Free cash flow per share
N/A
Book value per share
$1.14
Revenue per share
$0
TBVPS
$1.19
Total assets
$20.9M
Total liabilities
$4.58M
Debt
$342,000
Equity
$16.32M
Working capital
$15.54M
Debt to equity
0.02
Current ratio
4.57
Quick ratio
4.57
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-76.2%
Return on equity
-101.7%
Return on invested capital
-173%
Return on capital employed
-87%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMMB stock price
How has the Chemomab Therapeutics stock price performed over time
Intraday
3.13%
1 week
-1.49%
1 month
4.43%
1 year
197.3%
YTD
223.53%
QTD
5.1%
Financial performance
How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.37M
Net income
-$14.4M
Gross margin
N/A
Net margin
N/A
CMMB's net income has surged by 50% year-on-year and by 4% since the previous quarter
Chemomab Therapeutics's operating income has increased by 49% YoY and by 4.1% from the previous quarter
Growth
What is Chemomab Therapeutics's growth rate over time
Valuation
What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
1.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS has surged by 63% year-on-year and by 13% since the previous quarter
CMMB's equity has soared by 63% from the previous quarter but it is down by 10% YoY
CMMB's price to book (P/B) is 45% more than its 5-year quarterly average of 1.0 and 45% more than its last 4 quarters average of 1.0
Efficiency
How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has increased by 24% YoY and by 8% QoQ
The return on assets has increased by 15% year-on-year
CMMB's return on equity is up by 9% year-on-year
Dividends
What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMMB.
Financial health
How did Chemomab Therapeutics financials performed over time
CMMB's quick ratio is up by 46% from the previous quarter and by 10% YoY
Chemomab Therapeutics's current ratio has increased by 46% QoQ and by 10% YoY
The debt is 98% lower than the equity
CMMB's debt to equity has soared by 100% YoY but it has plunged by 50% from the previous quarter
CMMB's equity has soared by 63% from the previous quarter but it is down by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.